NEWS

WIRES

OTHER

iCAD Takes Leadership Position in Meeting the Need for Accredited Educational Initiatives on Prostate and Breast MRI Imaging Technologies

• Educate clinicians on the indications for use of MRI with prostate and breast cancer
  • Detection
  • Diagnosis
  • Staging
  • Treatment planning and monitoring
• Provide a detailed review of MRI images including case interpretation
• Review the technical aspects of breast and prostate MRI exams
• Guide clinicians in how to use MRI and advanced image analysis technology as part of the overall interpretation and standardization of reporting.

Four key areas have been consistently identified relative to prostate cancer MRI education and training; these include MRI indications and technique, MRI for cancer detection and localization, MRI for treatment planning and therapy monitoring, and future and evolving applications of prostate MRI. The prostate webinar series, "Common Practices in Prostate MRI," will include didactic lecture and case review.

Additionally, some of the nation's leading radiologists will deliver, "Decisions in Medical Imaging," a breast MRI webinar series. Based on recent evidence on the efficacy of breast MRI screening in high risk patients, the American Cancer Society issued guidelines for the early detection of breast cancer which include MRI. Additionally, MRI is emerging as an important tool in the treatment of breast cancer patients to evaluate the extent of disease, assess tumor response to neoadjuvant chemotherapy, and for surgeons in preoperative planning. This program brings to learners the opportunity to view a variety of breast MRI cases as expert faculty share their experience and approach to breast MRI in their own breast MRI practice.

"As a leader in advanced image analysis MRI solutions, iCAD is focused on continuing its educational initiative to improve the general understanding of how imaging protocols support earlier detection, better patient care and improved outcomes," said Ken Ferry, President and CEO of iCAD. "ICPME is a recognized leader in educational activities designed to improve practice performance and patient care. We look forward to working with them to provide valuable educational resources to clinicians who want to adopt MRI into their practices as this advanced imaging technique, when used with a quantitative image analysis software solution, has been proven to show improvements in cancer detection, treatment planning and management."

To receive notification for these upcoming educational sessions, please visit www.icadmed.com/newsevents/webinar.cfm, www.icpme.us or call 1-866-280-2239 ext. 7943.

About International Center for Postgraduate Medical Education (ICPME)

ICPME is a nationally accredited medical education company. The mission of ICPME is to provide independent, quality continuing education for physicians and other health care professionals with the goal being improved medical care for patients and communities. The company strives to provide high-quality, well-balanced educational programs of scientific rigor and integrity that are free from commercial bias. Located in Ithaca, New York, ICPME was first accredited by the ACCME in 1997 and ICPME is accredited to provide medical education for a multidisciplinary audience. More information can be found at: http://icpme.us/.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Since receiving FDA approval for the Company's first breast cancer detection product in 2002, more than 3,500 iCAD systems have been placed in healthcare practices worldwide. iCAD's solutions aid in the early detection of the most prevalent cancers including breast and prostate, and in the future colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.

**NOTE TO EDITORS, CAD MRI IMAGES AVAILABLE

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe" , "demonstrate" , "intend" , "expect" , "estimate" , "anticipate" , "likely" , and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

For iCAD
Darlene Deptula-Hicks, 603-882-5200 x7944
ddeptula@icadmed.com
or
For Investor Relations
Lippert/Heilshorn & Associates
Anne Marie Fields, 212-838-3777 x6604
afields@lhai.com
or
For media inquiries
MS&L PR
Liza Heapes, 617-369-8787
liza.heapes@mslworldwide.com